It does not provide instructions for human or veterinary use, dosing, injection, reconstitution, diagnosis, treatment, cosmetic use, or personal use.
Tesamorelin, also called TH9507, is a synthetic analog of human growth hormone-releasing hormone, or GHRH. It contains the 44-amino-acid human GHRH sequence, an N-terminal trans-3-hexenoyl group (a C6 chain with a double bond at position 3, attached to the N-terminal tyrosine residue), and a C-terminal amide.[1]

In laboratory testing, tesamorelin binds to and activates the human GHRH receptor. The main receptor pathway is Gs-adenylyl cyclase-cAMP signaling.
The receptor-structure study cited here (a cryo-electron microscopy structure at 2.6 Å resolution of the GHRH–GHRHR–Gs complex) used endogenous GHRH rather than tesamorelin, so it helps explain the likely pathway but should not be described as direct tesamorelin-structure data.[2][4]
Basic Molecular Information
| Item | Reference Information |
|---|---|
| Research name | Tesamorelin; TH9507 |
| Sequence | trans-3-hexenoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2 |
| Residue count | 44 amino-acid residues |
| Active-peptide formula | C221H366N72O67S |
| Average molecular mass (free base equivalent) | Approximately 5,135.9 Da |
| Monoisotopic mass | 5,132.7166 Da[3] |
| Tesamorelin active moiety CAS | 218949-48-5 |
| Tesamorelin acetate CAS | 901758-09-6[*] |
| Terminal structural features | N-terminal trans-3-hexenoylation; C-terminal Leu44 is amidated, consistent with the human GHRH(1–44)-NH2 form |
The FDA substance record confirms the 44-residue sequence and both terminal modifications.[1] PubChem lists the active-peptide formula, average molecular weight, and CAS number 218949-48-5 for the free base.[3]
The COA or product documentation should use the CAS number that matches the actual salt form supplied (active moiety or acetate).
Tesamorelin may also be supplied as an acetate salt. The official tesamorelin acetate description gives the formula as C221H366N72O67S · xC2H4O2, with x reported as about 7, while 5,135.9 Da is stated as the free-base equivalent.[2]
In that case, the peptide amount, acetate content, water, and other lot-specific components are separate measurements.
How Tesamorelin Activates the GHRH Receptor
- Receptor binding: In vitro data in the official label state that tesamorelin binds to and stimulates human GHRH receptors with potency similar to natural GHRH.[2]
- Receptor activation: GHRHR is a class B G protein-coupled receptor. Zhou et al. determined the cryo-electron microscopy structure of endogenous GHRH bound to human GHRHR in complex with the stimulatory Gs protein at 2.6 Å resolution.The structure showed that GHRH adopts an α-helical conformation and forms an extensive interaction network contacting all three extracellular loops (ECL1–3), the extracellular domain, and all transmembrane helices except TM4. The N-terminal region of GHRH engages a particularly broad set of specific interactions within the transmembrane binding pocket.[4]
This study used endogenous GHRH, not tesamorelin.
- cAMP signaling: After the receptor is activated, it couples mainly to the stimulatory G protein Gs. Gs activates adenylyl cyclase, which raises cAMP inside the cell.Early receptor-cloning work showed that GHRHR can produce both cAMP accumulation and cAMP-dependent gene activity in experimental cells.[5]
- Downstream response: Higher cAMP can activate protein kinase A and other cAMP-controlled processes. In cultured rat anterior pituitary cells, natural GHRH increased both growth hormone synthesis and growth hormone release, while somatostatin reduced the release response under the tested conditions.[6]This rat-cell study supports the general GHRH pathway, but it is not a direct tesamorelin experiment.
- Response over time: Repeated or prolonged receptor stimulation may lower later responses. Aleppo et al. found that treatment of cultured rat pituitary cells with GHRH (0.1 nM) for as little as 4 hours reduced GHRH-receptor mRNA levels to 49 ± 4% of control values, while GH release reached 320 ± 31% of control.GHRH pretreatment (10 nM) reduced subsequent GHRH-stimulated cAMP accumulation to 46% of untreated controls. The adenylate cyclase activator forskolin (10 μM) also reduced GHRH-R mRNA (to 37 ± 6% of control), indicating a cAMP-dependent mechanism, whereas the somatostatin analog octreotide (10 nM) did not affect GHRH-R mRNA levels.
Reduced receptor-binding sites had been reported in earlier desensitization studies as background, but binding capacity was not directly assayed in this particular study.[7] For this reason, time-course, washout, and repeat-challenge tests may be useful when studying tesamorelin in vitro.
Useful Laboratory Readouts
| Research Question | Possible Readout | Important Controls |
|---|---|---|
| Does the sample activate GHRHR? | cAMP response in cells that express human GHRHR | Vehicle, a qualified reference ligand, and cells without GHRHR |
| Is the signal linked to GHRHR? | Loss or reduction of the response after receptor removal or a validated receptor-pathway blocker | Matched control cells and a blocker-only control |
| Does the response change over time? | cAMP measured at several time points, followed by washout and repeat exposure | Time-matched untreated cells |
| Does the model show a secretory response? | Growth hormone measured in medium from a qualified pituitary-cell model | Vehicle, reference ligand, cell-viability check, and a matrix-matched standard curve |
There is no single concentration or incubation time that is correct for every assay.
The useful range depends on the cell line, receptor level, plate format, exposure time, and detection method. A dose-response test and a time-course test should be completed before one condition is treated as the working method.
How to Read a Tesamorelin COA
A certificate of analysis is specific to one batch. It can help confirm identity and quality, but no single result describes the whole batch.
- HPLC purity: The reported area percentage depends on the HPLC method and how peaks are separated and integrated. It should not be treated as the same thing as net peptide content.
- Mass spectrometry: An intact-mass result can support identity when the measured mass matches the expected value. The expected value must specify whether average mass (5,135.9 Da for the free base) or monoisotopic mass (5,132.7166 Da for the free base) is used. For LC–MS data, the report should identify the observed charge states and/or the deconvoluted neutral mass. A correct intact mass does not rule out every sequence-related impurity.
- Peptide content: Net peptide content may differ from total powder weight because the sample can also contain water, acetate or another counterion, and residual material from processing.
- Related impurities: Synthetic-peptide testing may need to consider deletion sequences, truncated sequences, insertion sequences, stereoisomers, and other process- or degradation-related variants.
- Other tests: Water, residual solvents, counterion level, bioburden, and endotoxin may be important depending on the planned laboratory assay.
The EMA synthetic-peptide guideline (EMA/CHMP/CVMP/QWP/367182/2025, effective 1 June 2026) calls for suitable characterization and control of peptide-related and process-related impurities.[8] ICH Q14 (effective 14 June 2024) also states that analytical methods should be suitable for their intended purpose and should be checked for performance and robustness.[9]
These pharmaceutical guidelines are cited as quality-development references and do not by themselves establish mandatory specifications for research-use-only material.
Solubility and Storage
Solubility and stability can change with salt form, peptide concentration, buffer, pH, temperature, light, oxygen, container material, and storage time. A statement such as “soluble at 1–5 mg/mL” or “stable at pH 6–8” should not be used as a universal rule unless it is supported by data for the same material and the same conditions.
Storage temperature should come from the batch-specific COA or supplier documentation. A general storage value, including -20 °C, should not replace actual stability data.
ICH Q1A(R2) stability guidance (effective 1 August 2003) explains that storage conditions and retest periods should be supported by studies that track quality over time; this guidance is written for new drug substance and drug product registration applications and does not set mandatory stability protocols for research-use-only materials.[10]
Any laboratory solution-preparation method should be written as an assay-reagent protocol and should state that it is not a human or veterinary dosing guide. This article does not provide reconstitution volumes, injection equipment, or dose calculations.
Limits of the Evidence
- A correct sequence or CAS number does not prove batch purity.
- A high HPLC area percentage does not prove identity, sterility, or peptide content.
- A correct intact mass does not rule out every sequence-related impurity.
- A cAMP response shows activity in that assay only.
- A result from rat pituitary cells must not be presented as a human result.
- Endogenous GHRH receptor-structure studies help explain the pathway, but they are not automatically tesamorelin-specific evidence.
Summary
Tesamorelin is a 44-residue GHRH analog with N-terminal trans-3-hexenoylation and a C-terminal amide consistent with the human GHRH(1–44)-NH2 form. In vitro, it activates the human GHRH receptor with potency similar to endogenous GHRH.
The best-supported pathway is receptor binding followed by Gs activation, adenylyl cyclase activity, and increased cAMP. Downstream growth hormone synthesis and release are supported by GHRH studies in pituitary-cell models, but each result must stay within the limits of the model that produced it.
Research References
- U.S. Food and Drug Administration, Global Substance Registration System. Tesamorelin substance record. FDA GSRS record.
- U.S. National Library of Medicine. DailyMed: EGRIFTA SV, Description (Section 11) and Mechanism of Action (Section 12.1). DailyMed record.
- National Center for Biotechnology Information. PubChem Compound Summary for Tesamorelin, CID 16137828. PubChem record.
- Zhou F, Zhang H, Cong Z, Zhao LH, Zhou Q, Mao C, Cheng X, Shen DD, Cai X, Ma C, Wang Y, Dai A, Zhou Y, Sun W, Zhao F, Zhao S, Jiang H, Jiang Y, Yang D, Xu HE, Zhang Y, Wang MW. Structural basis for activation of the growth hormone-releasing hormone receptor. Nature Communications. 2020;11:5205. doi:10.1038/s41467-020-18945-0. PubMed 33060564.
- Lin C, Lin SC, Chang CP, Rosenfeld MG. Pit-1-dependent expression of the receptor for growth hormone releasing factor mediates pituitary cell growth. Nature. 1992;360:765-768. PubMed 1334535.
- Fukata J, Diamond DJ, Martin JB. Effects of rat growth hormone-releasing factor and somatostatin on the release and synthesis of rat growth hormone in dispersed pituitary cells. Endocrinology. 1985;117:457-467. PubMed 2862007.
- Aleppo G, Moskal SF 2nd, De Grandis PA, Kineman RD, Frohman LA. Homologous down-regulation of growth hormone-releasing hormone receptor messenger ribonucleic acid levels. Endocrinology. 1997;138(3):1058-1065. doi:10.1210/endo.138.3.5029. PubMed 9048609.
- European Medicines Agency. Guideline on the Development and Manufacture of Synthetic Peptides (EMA/CHMP/CVMP/QWP/367182/2025, effective 1 June 2026). EMA guideline.
- International Council for Harmonisation. ICH Q14: Analytical Procedure Development (EMA/CHMP/ICH/195040/2022, effective 14 June 2024). ICH Q14.
- International Council for Harmonisation. ICH Q1A(R2): Stability Testing of New Drug Substances and Products (CPMP/ICH/2736/99, effective 1 August 2003). ICH Q1A(R2).
Research Use Only Disclaimer
Research Use Only: The tesamorelin material described on this page is supplied for laboratory research purposes only and not FDA-approved for human use. This article provides general scientific information regarding standard laboratory research contexts only, and does not constitute a validated experimental protocol, medical guidance, clinical guidance, veterinary guidance, or treatment advice.